HAE

As of 2026-10-26, HAE scores 63out of 100 on QNTM’s five-factor quantitative model, a high conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. HAE trades at $119.19, within its fair-value band.

HAE scores 63 out of 100 on QNTM's five-factor model — a high-conviction reading — 63 puts it among the strongest factor profiles the model tracks. Its strongest factor is momentum at 84 (exceptional), where price trend and relative strength are working in its favor, followed by value at 80. The weakest is sentiment at 45, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 7% of the Healthcare names the model scores.

On valuation, HAE is priced around the middle of its recent range. The blended composite before the macro overlay was 64. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on HAE, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where HAE sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for HAE runs $87.04–$141.28. Current price $119.19 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.